Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer (Breast Cancer Research and Treatment, (2019), 175, 2, (339-351), 10.1007/s10549-019-05166-3)

Jangsoon Lee, Bora Lim, Troy Pearson, Kuicheon Choi, Jon A. Fuson, Chandra Bartholomeusz, Linda J. Paradiso, Thomas Myers, Debu Tripathy, Naoto T. Ueno

Research output: Contribution to journalComment/debatepeer-review

Abstract

Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.” The first affiliations was incorrect in the original article. The correct information is given below.

Original languageEnglish (US)
Pages (from-to)251
Number of pages1
JournalBreast Cancer Research and Treatment
Volume176
Issue number1
DOIs
StatePublished - Jul 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer (Breast Cancer Research and Treatment, (2019), 175, 2, (339-351), 10.1007/s10549-019-05166-3)'. Together they form a unique fingerprint.

Cite this